spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  saxagliptin 

 HSMN NewsFeed - 19 Dec 2013
Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business
Biopharmaceuticals Endocrinology Acquisitions
 HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 23 Apr 2009
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 23 Jul 2008
Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 5 Dec 2007
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2007
James M. Cornelius Elected Bristol-Myers Squibb CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2007
Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 27 Dec 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 14 Dec 2006
OSI Pharmaceuticals Grants License to Bristol-Myers Squibb under Dipeptidyl Peptidase IV (DPIV) Patent Portfolio for the Treatment of Type 2 Diabetes
Biopharmaceuticals Licensing
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.